AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04963257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline fluvoxamine
Description: the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
Study NCT04963257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
Study NCT01148277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Remifentnyl
Description: Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
Study NCT01148277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and fentanyl
Description: Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
Study NCT01148277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam anf fentanyl
Description: group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
Study NCT02704533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
Study NCT02704533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (NF54)
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
Study NCT02704533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (NF54)
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
Study NCT02704533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (7G8)
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
Study NCT02704533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (7G8)
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
Study NCT02704533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% sodium chloride
Study NCT01315262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
Study NCT01733030 — intervention group
Intervention type: DRUG
Intervention: Seromycin
Description: 250 mg versus 500 mg versus placebo effects on conditioned fear generalization
Study NCT01733030 — intervention group
Intervention type: DRUG
Intervention: Seromycin
Study NCT04082000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-04
Description: BOL-DP-o-04
Study NCT04082000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00294112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal™ adult human mesenchymal stem cells
Description: Cells in plasmalyte and containing dimethylsulfoxide
Study NCT00294112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adult human mesenchymal stem cells
Description: two infusions, one week apart, each comprising adult human mesenchymal stem cells
Study NCT01844895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT00955630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
Study NCT00955630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: prn injections of ranibizumab throughout the study
Study NCT02851914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricyclic Antidepressants (TCA)
Description: if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
Study NCT02851914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective Serotonin Uptake Inhibitors (SSRI)
Description: if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
Study NCT02757170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thromboelastography
Description: Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
Study NCT02757170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thromboelastography
Description: Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
Study NCT03596372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834942
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.
Study NCT03515109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Altis tape
Description: placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
Study NCT03515109 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TVTO
Description: placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
Study NCT00855114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 5 mg/day x 7 days by mouth
Study NCT00855114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Definitive excision of breast cancer tissue
Study NCT01403337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic preconditioning
Description: The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
Study NCT01403337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A Blood Pressure cuff inflated to 40-50 mmHg
Study NCT02349178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
Study NCT02349178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
Study NCT02349178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
Study NCT03400722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris
Description: Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
Study NCT03400722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
Study NCT01088581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant group
Description: Adjuvant chemotherapy (5FU and cisplatin) after resection
Study NCT01509352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophageal stitches during fundoplication
Description: placement of esophageal stitches with fundoplication
Study NCT01509352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no esophageal stitches placed during fundoplication
Description: no esophageal stitches are placed during the fundoplication procedure
Study NCT02448511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
Study NCT02448511 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
Study NCT02448511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
Study NCT02448511 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
Study NCT02986230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CP-CDS
Description: The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
Study NCT02989792 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling for genotyping
Description: Venous punction of maximum 10 millilitres
Study NCT02989792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personality Questionnaires completion
Description: Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
Study NCT01318044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Thiopental
Description: An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved
Study NCT00603915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m\^2 intravenous (IV) day 1 and day 8
Study NCT00603915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Cisplatin
Description: Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
Study NCT00603915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg daily (post GC therapy)
Study NCT00758472 — intervention group
Intervention type: DEVICE
Intervention: ReCap Total Hip Resurfacing
Description: ReCap Total Hip Resurfacing
Study NCT01031914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paced Breathing
Description: The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
Study NCT03686501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two \[18F\]MNI-968 injections
Study NCT01145066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: borage/echium oil combination
Description: borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
Study NCT01145066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 1.6g/day EPA and 1.08g/day DHA
Study NCT01145066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: contains 4.5 g/day linoleic acid
Study NCT01182428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V®/ XIENCE PRIME™
Description: Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
Study NCT01182428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER SELECT
Description: XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
Study NCT03240146 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Pulsed Shortwave Therapy device
Study NCT03240146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Pulsed Shortwave Therapy device
Study NCT01009476 — intervention group
Intervention type: DRUG
Intervention: Galantamine
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
Study NCT01009476 — intervention group
Intervention type: DRUG
Intervention: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
Study NCT01282229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LANAP
Description: Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
Study NCT00802685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early ibuprofen
Description: IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen.
Study NCT00802685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Late ibuprofen expectant group (placebo)
Description: Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV.
Study NCT01487512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Hydromorphone 8 mg
Description: type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
Study NCT01487512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Hydromorphone 16 mg
Description: type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
Study NCT01487512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Hydromorphone 32 mg
Description: type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
Study NCT01487512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Hydromorphone 64 mg
Description: type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
Study NCT00428597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: * sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination.
Study NCT00428597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
Study NCT00983047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab and Docetaxel
Description: The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity.
Study NCT00983047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and Docetaxel
Description: The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity.
Study NCT03370497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Mineral Supplement
Description: Milk Minerals containing 1000 mg calcium
Study NCT03370497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Hydrolysate
Description: 50 g whey protein hydrolysate
Study NCT03370497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate
Description: 50 g whey protein hydrolysate
Study NCT02126085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular recanalisation
Description: Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept
Study NCT02126085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular recanalisation
Description: Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept
Study NCT03589404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rso2
Description: The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study NCT01132209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the abdominal wall after midline incisions
Description: Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
Study NCT01132209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the abdominal wall after midline incisions
Description: Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
Study NCT02095743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implanted port for chemo administration (X-port isp)
Study NCT02095743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of a PICC line for chemo administration (PowerPICC SOLO²)
Description: The description of the device could found on the published marketing authorisation
Study NCT02095743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a PICC line for chemo administration (PowerPICC SOLO²)
Description: The description of the device could found on the published marketing authorisation